Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (21-30 of 216) with videos related to

Pageof 22
Sort By:
Seminars in Oncology|March 27, 2007
Immunotherapeutic strategies for high-risk bladder cancerPadmanee Sharma, Lloyd J Old, James P Allison
Cell Reports. Medicine|May 2, 2022
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancerBilal A Siddiqui, Sumit K Subudhi, Padmanee Sharma
Nature Reviews. Immunology|June 13, 2022
Myeloid cell-targeted therapies for solid tumoursSangeeta Goswami, Swetha Anandhan, Deblina Raychaudhuri, et al.
Trends in Cancer|May 31, 2023
Neuro-immune interactions and immuno-oncologyNarmina Khanmammadova, Shajedul Islam, Padmanee Sharma, et al.
Nature Immunology|November 26, 2024
Next-generation combination approaches for immune checkpoint therapySangeeta Goswami, Kristen E Pauken, Linghua Wang, et al.
Cancer Discovery|May 16, 2012
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptideJingjing Sun, Derek Ng Tang, Tihui Fu, et al.
Cancer Cell|March 21, 2025
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefitKristen E Pauken, Omar Alhalabi, Sangeeta Goswami, et al.
Cell|October 8, 2021
Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeGolnaz Morad, Beth A Helmink, Padmanee Sharma, et al.
Current Opinion in Immunology|May 31, 2016
Monitoring immune responses in the tumor microenvironmentJennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, et al.
Cell|February 11, 2017
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyPadmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, et al.
Pageof 22

Showing results (21-30 of 216) with videos related to

Sort By:
Pageof 22
Seminars in Oncology|March 27, 2007
Immunotherapeutic strategies for high-risk bladder cancerPadmanee Sharma, Lloyd J Old, James P Allison
Cell Reports. Medicine|May 2, 2022
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancerBilal A Siddiqui, Sumit K Subudhi, Padmanee Sharma
Nature Reviews. Immunology|June 13, 2022
Myeloid cell-targeted therapies for solid tumoursSangeeta Goswami, Swetha Anandhan, Deblina Raychaudhuri, et al.
Trends in Cancer|May 31, 2023
Neuro-immune interactions and immuno-oncologyNarmina Khanmammadova, Shajedul Islam, Padmanee Sharma, et al.
Nature Immunology|November 26, 2024
Next-generation combination approaches for immune checkpoint therapySangeeta Goswami, Kristen E Pauken, Linghua Wang, et al.
Cancer Discovery|May 16, 2012
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptideJingjing Sun, Derek Ng Tang, Tihui Fu, et al.
Cancer Cell|March 21, 2025
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefitKristen E Pauken, Omar Alhalabi, Sangeeta Goswami, et al.
Cell|October 8, 2021
Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeGolnaz Morad, Beth A Helmink, Padmanee Sharma, et al.
Current Opinion in Immunology|May 31, 2016
Monitoring immune responses in the tumor microenvironmentJennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, et al.
Cell|February 11, 2017
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyPadmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, et al.
Pageof 22